Abstract 3118: IBI3026, a first-in-class anti-PD-1/IL-12 fusion protein, demonstrates the potential to be a new immuno-oncology therapy by releasing the break in immune response and strongly activating T and NK cells in the tumor microenvironment

Authors: Xinran Liu, Fenggen Fu, Shuaixiang Zhou, Weiwei Wu, Haoyu Wen, Yang Liu, Min Wu, Meng Ni, Yan Liu, Enhong Zhong, Yayao Yan, Ying Zhang, Zhihai Wu, Yuting Wei, Kaijie He

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-3118

Source: Full article